A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and
expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid
leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysp...
Age: 18 years - 66+
Gender: All
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when
administered at the maximum approved dose in low-risk Myelodysplastic Syndrome
participants who require red blood cell transfusions.
Age: 18 years - 66+
Gender: All
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1
interventional, open-label, biologic assignment-based umbrella study evaluating the
feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2
doses of TSC-10...
Age: 18 years - 66+
Gender: All
Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Age: 18 years - 66+
Gender: All
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Age: 18 years - 66+
Gender: All
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML
Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1
consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at
escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be
escalated at...
Age: 18 years - 66+
Gender: All
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
This trial will evaluate magrolimab, a monoclonal antibody which is designed to block a
protein called CD47, which is widely expressed on human cancer cells. Blocking CD47 with
magrolimab may enable the body's immune system to find and destroy the cancer cells. In thi...
Age: 18 years - 66+
Gender: All
Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)
This study is designed as a multicenter trial, with biological assignment to one of two study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
Age: 50 - 75 years
Gender: All